Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
European Journal of Cancer2020Vol. 136, pp. 25–34
Citations Over Time
Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz, Karine Le Malicot, Bidaut Wahiba, Samy Louafi, Alain Gratet, Laurent Miglianico, H. Laharie, Karine Bouhier Leporrier, Anne Thirot Bidault, Patrick Texereau, Romain Coriat, Eric Terrebonne, Marie-Claude Gouttebel, David Malka, Jean‐Baptiste Bachet, Côme Lepage, Julien Taı̈eb, Cécile Julien, Nicolas M. Barrière, Julie Gigout, Simon Pernot, Céline Lepère, Aziz Zaanan, Géraldine Perkins, Raymond Despax, J. Chamois, Xavier Artignan, Pauline Regnault, Benoît Dupont, Maxime Lesouef, L. Bengrine Lefevre, Julie Vincent, François Ghiringhelli, Mme E. Barbier, Morgan Andre, Johann Dréanic, Catherine Brezault‐Bonnet, Valérie Boige, Antoine Holllebecque, B. Valenza, Gildas Phelip, Philippe Dominici, Marion Chauvenet, Frédérick Moryoussef, Pierre-Luc Etienne, Dominique Besson, Mathilde Martinez, Pamela Biondiani, Benoît Avisse, Marie‐Pierre Galais, Aurélie Parzy, Salvatore Caruso, Jean-François Codoul, Iulia Pripon, Mustapha Atlassi, Oana Cojocarasu, Etienne Suc, Ahmed Bedjaoui, Philippe Houyau, Yann Bergé, D. Gargot, Vincent Bourgeois, Pierre-Emmanuel Henneresse, S. Lavau Denes, Valérie Lebrun Lyat, Dominique Genet, Jean Martin, Pr Pierre Michel, David Sefrioui, Anne Escande, Louis-Marie Dourthe
Related Papers
- → Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study(2008)27 cited
- → FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study.(2020)3 cited
- → Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype(2017)2 cited
- → Sequential or combination chemotherapy for a patient with mCRC?(2008)
- [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].(2015)